Miruvor
Sign up
The short answer

What studies of Fluvoxamine (Luvox) found

24papers on Fluvoxamine (Luvox)
150people in 1 study testing Fluvoxamine (Luvox) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: B May help

Based on the strongest evidence, the placebo trial (low certainty), for fatigue.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Fluvoxamine (Luvox) may help for long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 24 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. Fluvoxamine (Luvox) · Long COVID is hereB
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Fatigue1 study · 150 people took Fluvoxamine (Luvox) Improvement B
Low certainty

Why this grade: Improvement, low certainty, from randomised trials: some concerns about bias (RoB 2); few people (399 in all).

The placebo trial399 randomised · 60 days with follow-up to day 90 · 100 mg BID, twice daily (BID) for 60 days

Fatigue improved more than in the comparison group.

Fluvoxamine (Luvox) may reduce fatigue in long COVID. Improvement · low certainty B

  • Some concerns about bias (RoB 2)
  • Few people (399 in all)
See the 1 study
  1. Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial. (2026)

    People in the study
    399 randomised
    Dose
    100 mg BID, twice daily (BID) for 60 days
    Outcome
    Change in FSS score from baseline to day 60 Fatigue Severity Scale
    Effect
    better
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns
Low mood or anxiety1 study · 150 people took Fluvoxamine (Luvox) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 399 people found no clear difference; a small benefit can't be ruled out.

The placebo trial399 randomised · 60 days with follow-up to day 90 · 100 mg BID, twice daily (BID) for 60 days

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of fluvoxamine (Luvox) on low mood or anxiety in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 399 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial. (2026)

    People in the study
    399 randomised
    Dose
    100 mg BID, twice daily (BID) for 60 days
    Outcome
    treatment by baseline anxiety or depression Fatigue Severity Scale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Some concerns
    Deviations from intended interventions
    Low
    Missing outcome data
    High
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

No study of this treatment alone reported side effects we could read.

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    50 to 100 mg at the start in most studies

  2. 2Raise

    Raised step by step in 2 of 7 studies

  3. 3Top dose

    Most often 50 mg (3 of 7 studies)

Doses across 7 studies

50 to 100 mg. One study went up to 300 mg.

Each study’s dose, as printed

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

Systematic reviewPublished 2026Searched to May 20, 2024

[The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update]. (2026)

“there is promising evidence of a preventive effect of AD (especially fluvoxamine) against progression to severe COVID-19 and against the development of Long COVID.”
“A direct comparative clinical trial with approved antiviral agents is still pending and should be positive to further open the door for a guideline-based recommendation of fluvoxamine (or perhaps even AD) for COVID-19 or its aftermath.”

Meta-analysisPublished 2024Searched to from the outbreak of SARS-CoV-2 in late 2019 until January 2024

A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications. (2024)

“fluvoxamine has shown some potential for treating COVID-19 infection, preventing clinical deterioration and mortality. There also appears to be an optimal timing and dose, with early treatment and higher doses being optimal.”
“Furthermore, there is the potential for the prevention of Long-covid symptoms in those who were initially treated for COVID-19 with fluvoxamine. Further study on this is required.”
“Five studies examined the long-term effects of fluvoxamine in preventing Long-covid, with three already having published data. Overall, these trials indicated a lack of success.”

All papers

  1. Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.2026 · placebo trial · 399 randomised
    Summary

    This randomized, placebo-controlled, adaptive trial assessed fluvoxamine and metformin for fatigue in long COVID. It enrolled 399 adults with fatigue 90 days to 24 months after confirmed SARS-CoV-2 infection at 22 outpatient sites in Brazil between October 2023 and February 2025. Participants received oral fluvoxamine 100 mg twice daily (n = 150), metformin (n = 111; 750 mg twice daily, n = 71, or 500 mg twice daily, n = 40), or matching placebo (n = 138), each for 60 days with follow-up to day 90. The primary measure was change in Fatigue Severity Scale score. At day 60, fluvoxamine versus placebo showed a mean treatment effect of -0.43 points (95% CrI, -0.80 to -0.07) and a 99.0% posterior probability of superiority; at day 90 the difference was -0.58 (CrI, -0.98 to -0.16) with 99.7%. Metformin findings were inconclusive: day 60 effects were -0.02 (CrI, -0.48 to 0.44) for 750 mg and -0.04 (CrI, -0.63 to 0.54) for 500 mg. Fluvoxamine improved quality-of-life scores at day 60 (0.06 [CrI, 0.01 to 0.11]) and day 90 (0.07 [CrI, 0.00 to 0.14]); metformin showed no meaningful improvement. Recovery risk ratios were 1.36 at day 60 and 1.19 at day 90 for fluvoxamine; metformin CrIs included 1.0. Adverse events occurred in 36 (24.0%) fluvoxamine participants, 32 (45.1%) metformin 750 mg, 17 (42.5%) metformin 500 mg, and 49 (35.5%) placebo participants. Grade 3 or higher events were rare (2.7%), with no treatment-related deaths. The metformin dose was reduced after a 9% rate of gastrointestinal adverse effects prompting withdrawal, and the metformin group was stopped for futility; fluvoxamine was stopped for superiority.

  2. Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 Trial2023 · placebo trial · 1,323 randomised
    Summary

    COVID-OUT was a decentralized, multi-site trial in the United States that asked whether outpatient treatment with metformin, ivermectin, or fluvoxamine could prevent Long COVID. It randomized 1323 participants; 1125 consented to long-term follow-up, and 95.1% completed >9 months of follow-up. Inclusion criteria included age 30 to 85 years with overweight or obesity and symptoms. The trial used parallel factorial assignment to three medications or matched placebo. The abstract does not report treatment duration. The outcome described was Long COVID, defined in the abstract as a medical provider diagnosis. Overall, 8.4% reported a provider diagnosis of Long COVID. Cumulative incidence was 6.3% with metformin and 10.6% with matched placebo. The hazard ratio for metformin preventing Long COVID was 0.58 (95%CI, 0.38 to 0.88; P=0·009) versus placebo. The authors also report a 42% relative decrease and 4.3% absolute decrease in Long COVID incidence with early outpatient metformin compared with exact-matching placebo. The abstract does not report Long COVID results for ivermectin or fluvoxamine. It also does not report side effects, withdrawals, or people who worsened. The abstract does not state limitations.

  3. Effectiveness of early-treatment interventions on self-reported long COVID: A multi-arm, multi-stage adaptive platform control trial2023 · placebo trial · 5,700 analysed · preprint
    Summary

    This multi-arm, multi-stage adaptive platform trial asked whether early COVID-19 treatments prevent long COVID. The analysis included 5,700 patients at 12 primary care and emergency department outpatient clinics in Minas Gerais, Brazil; the primary outcome was persistence of COVID-19 symptoms at 60 days after randomization. Patients received doxazosin, fluvoxamine, fluvoxamine plus inhaled budesonide, interferon-lambda, ivermectin, or metformin, or matching placebo; durations were 10 days for doxazosin, fluvoxamine, fluvoxamine-budesonide and metformin, a single dose for interferon-lambda, and 3 days for ivermectin. Overall, approximately 22% reported at least one ongoing symptom at 60 days regardless of the early treatment they received. By Day 28, 80% reported recovery; by Day 60, 90% reported recovery. The abstract reports no statistical benefit of any intervention on recovery, cure fractions, or PROMIS scores, while the results text says only doxazosin showed a significant reduction in symptoms relative to placebo (p = 0.026). At Day 60, 41% continued to report poor or fair Physical Health. Side effects and withdrawals from harms were not reported. The authors state that major limitations primarily concern reliance on self-reported data.

  4. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.2023 · placebo trial · 1,431 randomised · 1,323 started · 1,126 analysed
    Summary

    COVID-OUT was a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial at six US sites, recruited remotely, asking whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce long COVID. 1431 people were enrolled and randomly assigned; 1323 received a dose, and 1126 consented for long-term follow-up and completed at least one survey after day 180. Participants received metformin up to day 14, ivermectin for 3 days, or fluvoxamine up to day 14, each compared with matched placebo. The outcome was long COVID diagnosis by a medical provider by day 300. Cumulative incidence was 6·3% with metformin and 10·4% with matched placebo (HR 0·59, 95% CI 0·39–0·89; p=0·012). Ivermectin was 7·7% vs 8·1% (HR 0·95, 95% CI 0·57–1·59) and fluvoxamine 10·1% vs 7·5% (HR 1·36, 95% CI 0·78–2·35); neither had a significant effect. By day 28, hospitalisation was eight [1·3%] of 596 with metformin vs 19 [3·2%] of 601 with placebo (HR 0·42, 95% CI 0·18–0·95). Adverse events did not significantly differ between treatment groups. Withdrawals due to harms were not reported; 28 (5·0%) of 564 metformin and 24 (4·3%) of 562 placebo were lost to follow-up before day 270.

  5. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.2023 · placebo trial · 100 randomised · 85 analysed
    Summary

    This randomized placebo-controlled double-blind trial asked whether fluvoxamine during active COVID-19 prevents post-COVID syndrome (PCS) neuropsychiatric symptoms. It enrolled 100 outpatients above 18 years old with confirmed mild to moderate COVID-19 at Besat hospital, Tehran, Iran; 50 were assigned to fluvoxamine 100 mg tablet daily for 10 days and 50 to placebo daily for 10 days. At 12 weeks, 85 patients were analysed (42 fluvoxamine, 43 placebo). The primary outcome was fatigue, measured with the Fatigue Assessment Scale (score >22); secondary outcomes included other PCS neuropsychiatric symptoms. Fatigue was significantly lower with fluvoxamine: 9 (21.4%) vs 19 (44.2%), p=0.026, relative risk 0.48 (95% CI 0.25–0.95). PCS overall was 32 (76.2%) vs 35 (81.4%), p=0.557, relative risk 0.93 (95% CI 0.75–1.16). No significant differences were observed in other symptoms; depression was 1 (2.4%) vs 7 (16.3%), p=0.058, relative risk 0.14 (95% CI 0.02–1.13). Nine patients discontinued medication and six could not be contacted. Side effects were not reported; serious symptoms such as dyspnea, confusion, and chest pain were evaluated at the 1-week and 12-week follow-ups.

  6. Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up.2022 · placebo trial · 1,323 started · 1,125 analysed · preprint
    Summary

    COVID-OUT was a phase 3, randomized, quadruple-blinded placebo-controlled trial in the US. It asked whether early outpatient treatment of SARS-CoV-2 with metformin, ivermectin, or fluvoxamine prevents Long Covid. The trial enrolled 1,125 adults age 30 to 85 with overweight or obesity, fewer than 7 days of symptoms, and within three days of a documented SARS-CoV-2 infection. Participants received metformin titrated to 1,500mg per day for 14 days total, ivermectin 390–470 mcg/kg per day for 3 days, fluvoxamine 50mg on day one then 50mg twice daily through 14 days, or exact-matching placebo. The outcome was participant-reported medical-provider diagnosis of Long Covid by day 300 after randomization. Overall, 8.4% (94/1125) reported a Long Covid diagnosis. For metformin versus blinded control, cumulative incidence was 6.2% (95% CI 4.2% to 8.2%) versus 10.6% (8.0% to 13.1), with Hazard Ratio 0.58 (95% CI 0.38 to 0.88) and p=0.009. For ivermectin, cumulative incidence was 8.0% (95% CI 5.2% to 10.8%) versus 7.5% (95% CI 4.7% to 10.2%), HR 0.99 (0.59 to 1.64). For fluvoxamine, cumulative incidence was 10.1% (95% CI 6.6% to 13.5%) versus 7.5% (95% CI 4.4% to 10.5%), HR 1.36 (0.79 to 2.39). The paper states no decreased incidence attributable to ivermectin or fluvoxamine. In the first 28 days, 1.34% (8/596) of those receiving metformin were hospitalized or died compared to 3.16% (19/601) of blinded controls. The paper did not report side effects, and did not report withdrawals for harms. Limitations included the changing definition of Long Covid and exclusion of low-risk individuals.

  7. Fluvoxamine and long COVID: Post-acute recovery.2024 · randomised trial
    Summary

    This paper reports long-term recovery outcomes from two 15-day clinical trials of fluvoxamine (200 or 300 mg per day) for acute COVID-19, the STOP COVID 1&2 trials, in people later assessed for post-acute recovery after acute COVID-19. Participants were compared with a placebo group. Recovery was measured by self-report on a 0–100 scale as the percentage recovered back to pre-COVID baseline; follow-up was 3–7 months later in STOP COVID 1 and 90-day follow-up in STOP COVID-2. In STOP COVID 1, 102 participants (67%) completed follow-up questionnaires. In STOP COVID-2, 419 individuals (77%) answered at 90-day follow-up. From the combined trials, 8% of those who took fluvoxamine and 15% of those who took placebo reported being <60% recovered at long-term follow-up (Fisher’s exact test p=0.019). In STOP COVID 1, 3 (6%) of those who took fluvoxamine reported being <60% recovered at follow-up, compared to 7 (15%) of those assigned to placebo; in STOP COVID 2, 17 (9%) of those who took fluvoxamine reported being less than 60% recovered at 90-day follow-up, compared to 32 (15%) of those assigned to placebo. Across both trials, only 30% of participants reported being 100% recovered back to baseline, with no differences between fluvoxamine and placebo. For harms, the text notes that only individuals in the placebo group deteriorated in STOP COVID 1; side effects and withdrawals for harms were not reported. Limits include incomplete follow-up response rates (67% and 77%), with lower response among those who clinically deteriorated (30% and 68%). The setting was not reported.

  8. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.2024 · randomised trial · 1,900 randomised · 995 analysed
    Summary

    This open-label, multi-arm, randomized controlled trial in Thailand compared early treatment in adults with confirmed mild SARS-CoV-2 infection within 48 h of symptoms. The text reports 1900 underwent randomization and 995 completed the trial. Treatment-as-randomised arm sizes were standard care 336, fluvoxamine 162, fluvoxamine plus bromhexine 178, fluvoxamine plus cyproheptadine 147, and niclosamide plus bromhexine 172. Fluvoxamine was given orally at 50 mg for 14 days; bromhexine 8 mg for 10 days; cyproheptadine 4 mg for 14 days; niclosamide 1000 mg for 14 days. Clinical status was measured on a 6-point scale at days 9, 14, and 28, post-acute sequelae of COVID-19 (PASC) symptoms at 90 days after treatment, and adverse events for 14 days after randomisation. For the primary endpoint, the text reports 9 of 163 in the fluvoxamine arm, while the table lists 162 in that arm. Any PASC symptoms were reported by 336 (100.0%) standard-care participants, 97 (59.9%) fluvoxamine, 87 (48.9%) fluvoxamine plus bromhexine, 76 (51.7%) fluvoxamine plus cyproheptadine, and 70 (40.7%) niclosamide plus bromhexine. Serious adverse events occurred in 23 (6.8%) standard-care participants, 1 (0.6%) fluvoxamine participant, and 0 in the combination arms; no deaths occurred. Gastroenteritis, nausea, or vomiting occurred in 40 (24.7%) fluvoxamine participants and 27 (8.0%) standard-care participants. The text reports 905 withdrawn after randomisation in Results and 593 not receiving treatment after randomisation in Discussion.

  9. Immunoadsorption to treat patients with severe post-COVID syndrome.2023 · case report · 178 in the study
    Summary

    This study asked whether removing autoantibodies with immunoadsorption (IA) would relieve symptoms in post-COVID syndrome. The authors invited adults who attended the post-COVID outpatient clinic of Jena University Hospital between July 2021 and November 2021. They enrolled and collected serum samples from 178 patients diagnosed with post-COVID syndrome; 101/178 had elevated levels of at least one autoantibody. Two of the study participants with severe post-COVID syndrome and high autoantibody levels underwent five cycles of IA with IgG-binding columns over the course of 2 weeks. There was no comparison group. Severity was assessed with the Global Assessment Scale, the Patient Health Questionnaire-9, the Fatigue Assessment Scale and the Montreal Cognitive Assessment, before IA, after IA and at follow-up (Case #1, 30 days; Case #2, 21 days). In Case #1, GAS was 40 before IA, 70 after IA and 50 at 30-day follow-up; FAS was 39 before IA, 20 after IA and 32 at 30-day follow-up; PHQ-9 was 12 before IA, 6 after IA and 8 at 30-day follow-up. In Case #2, GAS was 40 before IA, 40 after IA and 30 at 21-day follow-up; FAS was 23 before IA, 20 after IA and 17 at 21-day follow-up; PHQ-9 was 10 before IA, 3 after IA and 3 at 21-day follow-up. Clinical remission was achieved in one of two patients, and this patient relapsed within 6 weeks. Hypotension, as a mild adverse event, resulted in the termination of the first IA in Case #2 after 184 minutes. The authors state the main limitation was the very limited number of patients who underwent IA treatment.

  10. [The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update].2026 · systematic review
    Summary

    This systematic scoping review searched PUBMED on May 20, 2024 and identified 1016 articles related to antidepressants and COVID-19, Long COVID and SARS-COV-2. It included 10 retrospective “large scale” studies (> 20000 chart reviews), 8 prospective clinical trials (plus 4 regarding Long COVID), 11 placebo-controlled randomized (RCT) (plus 2 regarding Long COVID) and 15 meta-analyses. The review reports retrospective studies of antidepressants, most studied SSRIs and SSNRIs, associated with significantly fewer SARS-COV-2 infections and a milder course of COVID-19. 12 out of 15 meta-analyses referred to fluvoxamine and found a significant (40-70% reduction) in mortality, intubation and hospitalization rates when fluvoxamine was used as an add-on to standard therapy for mild to moderate COVID-19. A dose dependency was observed: 2x50 mg fluvoxamine over 15 days was less effective than 2x100 or even 3x100 mg, with an adverse event profile still at the placebo level. An indirect meta-analytical comparison showed an advantage of paxlovid or molnupiravir versus fluvoxamine: risk reduction of 95% or 78% versus 5+-5%. An add-on of fluvoxamine was still significantly more efficacious than symptom-oriented standard therapy alone. For Long COVID, a phenotype with anxiety and depression symptoms responds to AD, relaxation therapy and/or psychotherapy; casuistics report positive effects of AD on fatigue, cognitive and autonomic dysfunctions. A first large prospective open-label RCT showed significantly more favourable courses, less viral load and less pro-inflammatory cytokines with fluvoxamine versus standard treatment, also regarding subsequent neuropsychiatric and pulmonary Long COVID or fatigue. Worsening and discontinuation counts were not reported.

  11. Long COVID: A Systematic Review of Preventive Strategies.2025 · systematic review
    Summary

    This systematic review asked whether treatments can prevent long COVID, defined as symptoms lasting three or more months after SARS-CoV-2 infection. The authors searched PubMed/MEDLINE for articles published between December 2019 and September 2024 and included 28 studies: fifteen on COVID-19 vaccination, seven on antivirals, and six on other treatments. Findings are reported study by study rather than pooled. For vaccination, ten out of fifteen studies demonstrated a protective effect against long COVID; Ayoubkhani et al. reported odds decreased by 12.8% after a first dose and by an additional 8.8% after a second dose compared with unvaccinated individuals, while Antonelli et al. found a booster did not reduce risk when long COVID was defined as symptoms lasting 12 weeks or longer. For antivirals, a randomized trial of remdesivir found no significant differences between treated and untreated groups, whereas Boglione et al. reported a 36% reduction in odds with remdesivir and Wang et al. reported nirmatrelvir/ritonavir reduced odds by 65%. Convalescent plasma showed no statistically significant reduction; metformin showed a 42% reduction in long COVID incidence; multiple micronutrient supplements for 2 weeks showed no differences. Luo et al. reported vaccination after infection increased risk of reporting long COVID symptoms, which may be due to side effects. No stopping data were recorded. The authors state that COVID-19 vaccines likely reduce the risk of developing long COVID, while evidence for antivirals and other drugs is still in its infancy.

  12. Preventive interventions for post Covid-19 condition: systematic review update2024 · systematic review · preprint
    Summary

    This systematic review update searched on February 9, 2024 and included 24 studies (5 randomized and 19 non-randomized), all among adults. It examined interventions given during acute or post-acute COVID-19 to prevent post COVID-19 condition (PCC). For convalescent plasma in outpatients (1 trial; N=882), the RR (95% CI) was 0.93 (0.77-1.12), with moderate certainty. For probiotics in outpatients (1 trial; N=69), RR was 0.32 (0.13-0.78), low certainty. For metformin in outpatients (1 trial; N=450), RR was 0.50 (0.25-0.99), low certainty. For ivermectin in outpatients (1 trial; N=374), RR was 0.93 (0.50-1.71), low certainty. Therapeutic-dose heparin versus prophylactic-dose heparin in inpatients (1 trial; N=571) had RR 1.11 (0.94-1.30) for PCC, low certainty; for cognitive impairment RR was 0.49 (0.22 to 1.07), low certainty; and for HRQoL the MD was 0.12 (-3.22 to 3.46) [range 0-100], moderate certainty. In one trial, metformin (n=569) had no serious adverse events per group; fluvoxamine (n=319), ivermectin (n=406), metformin and fluvoxamine (n=336), and metformin and ivermectin (n=401) had no events in any comparison.

  13. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether fluvoxamine prevents clinical deterioration and death in COVID-19 and affects Long-COVID. It covered 14 studies and 7153 patients with acute COVID-19 or Long-COVID complications; patients were not ME/CFS. Fluvoxamine was given at different doses (for example 50 mg or 100 mg twice daily, or 300 mg/day) for different durations and compared with placebo or standard care. Outcomes included clinical deterioration, death, time to sustained recovery, and Long-COVID diagnosis or symptoms. Across all 14 studies, 681/3553 in standard care and 255/3600 in the fluvoxamine group experienced clinical deterioration. In seven placebo-controlled studies, 237/2573 in standard care and 150/2507 in the fluvoxamine group suffered clinical deterioration. For death, 182/3791 in standard care and 61/3931 in the fluvoxamine group died. Some trials found no significant difference: ACTIV-6 Arm B had 27/646 versus 26/588 healthcare utilization events and no deaths; Soe et al. had 2/26 versus 2/26 clinical deterioration. In COVID OUT, 7.5% of controls and 10.1% of fluvoxamine patients reported a Long-COVID diagnosis; fluvoxamine did not decrease the likelihood. Side-effect counts were not reported in the recorded data.

  14. Experimental drugs in randomized controlled trials for long-COVID: what's in the pipeline? A systematic and critical review.2023 · systematic review
    Summary

    This systematic and critical review asked whether experimental drugs for long-COVID have been tested in randomized controlled trials, searching three databases on 21st March 2023. It included 4 completed and 22 ongoing trials. The completed trials came from Brazil, Russia, the U.S., and Finland. In Barros et al. (2021), 118 hospitalized COVID-19 patients received methylprednisolone or placebo; at day-120, FVC was 3.2 ± 0.8 vs. 2.9 ± 0.8 (P = .01), with no changes in 6MWD, functional capacity by DASI, or other lung functions. Bazdyrev et al. (2022) gave Treamid or placebo to 60 survivors with fibrotic lung changes; at week-4, FVC and DLCO increased (41% vs. 17%, P < .05) and Borg dyspnea decreased (−0.9 ± 0.7 vs. −0.4 ± 0.8, P < .05), but 6MWD, mMRC dyspnea, CT score, KBILD, and other pulmonary function showed no improvement; frequency of adverse events was unchanged. Bramante et al. (2022) randomized 1,125 COVID-19 patients with overweight or obesity: metformin lowered long-COVID diagnosis (6.3% vs. 10.6%) and risk (HR = 0.58, 95% CI 0.38–0.88) at day-300; ivermectin and fluvoxamine showed no changes. Nevalainen et al. (2022) randomized 181 hospitalized patients to remdesivir or standard care; at year-1 there were no changes in recovery, quality of life, or long-COVID symptoms.

  15. The role of peripheral serotonin in SARS-CoV-2 infectivity, COVID-19 treatment and long COVID.2026 · review
    Summary

    This review assessed the gastrointestinal effects of COVID-19, gut-derived serotonin, and selective serotonin reuptake inhibitors (SSRIs) in COVID-19 and long COVID. It did not enroll or treat its own patients; it summarized other studies, and the setting and number of reviewed studies were not reported. In a 2020 double-blind, placebo-controlled randomized trial, clinical deterioration occurred in 0 of 80 fluvoxamine patients and 6 in 72 (8.3%) placebo patients, and the placebo group reported more GI symptoms. A 2021 randomized, placebo-controlled adaptive platform trial reported a 5% absolute risk reduction and a 32% relative risk reduction in hospitalization with fluvoxamine. A 2021 to 2022 open-label randomized outpatient trial enrolled 1900 participants (995 completed); fluvoxamine, fluvoxamine plus bromhexine, and fluvoxamine plus cyproheptadine had less clinical deterioration at 9, 14 or 28 days than standard care, and combination treatments had decreased viral loads at day 5, decreased serum cytokines, and lower long COVID-19 symptoms. A meta-analysis found 100 mg twice daily fluvoxamine associated with reduced mortality, hospitalization and composite hospitalization/emergency room visits, while 50 mg twice daily did not. A 1288-outpatient trial with 50 mg twice daily for 10 days found no shortened symptom duration, and a 1175-participant trial with 100 mg twice daily did not shorten symptoms. A 95-patient post-COVID study reported all improved and approximately two-thirds had a good to strong SSRI response. A retrospective analysis associated SSRIs with a significant decrease in Postacute sequelae of COVID-19 risk. The authors state limitations include heterogeneity in long COVID definitions and remaining debate.

  16. The Post-COVID syndrome caused by excessive inflammation: pathogenesis, potential targets and therapeutic agents.2026 · review
    Summary

    This review examined pharmacological interventions for post-COVID syndrome (PCS) predominantly characterised by persistent fatigue, with no participants of its own. It summarised studies of CoQ10 plus ALA, cacao flavonoids, amantadine, L-arginine plus vitamin C, fluvoxamine, astragalus root extract, Myelophil/MYPplus, Paxlovid, abrocitinib, upadacitinib, AXA1125, oxaloacetate, nicotinamide riboside, fexofenadine plus famotidine and IVIg. In a prospective observational study, 174 people with long COVID were enrolled and 116 received CoQ10 plus ALA; 53.5% had a complete FSS response versus 3.5% in the control group, and the non-response rate was 9.5% versus 25.9%. A cacao flavonoid trial (n = 46) reported improvements after 90 days. An open-label amantadine trial enrolled 83 patients; after 2 weeks scores were significantly superior to control (P < 0.001). A single-blind trial in 46 patients reported fatigue in 8.7% with L-arginine plus vitamin C versus 80.1% with placebo at day 28 (p < 0.0001). A fluvoxamine trial enrolled 399 patients and reduced FSS scores at day 60 and day 90; the fluvoxamine group had a lower incidence of adverse events, with rare serious adverse reactions. An astragalus trial reported chronic fatigue prevalence falling from 100% to 13.8%, and 17.2% one month later, versus 80.0% and 70.0% with placebo (P < 0.0001). A phase IIa AXA1125 trial found no overall differences in objective mitochondrial function between treatment and placebo. Amantadine was well tolerated with no notable safety concerns; astragalus had no obvious adverse reactions. Current evidence is mainly from observational studies or small-sample RCTs and is insufficient as definitive evidence of efficacy.

  17. Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review.2025 · review
    Summary

    This scoping review asked which therapeutic agents can be used for post-acute sequelae of COVID-19 (PASC). The authors searched PubMed, Embase, and the Cochrane library for English studies published between January 1, 2020, and July 22, 2024; 413 studies were identified and 39 were included. The review did not report a total number of participants. Included reports measured symptoms such as fatigue, pain, cognitive function, olfactory function, pulmonary function, PASC incidence, hospitalization, and death. For metformin, among 1126 patients observed for nine months, 93 (9.3%) reported PASC, with a hazard ratio of 0.59 (95% CI 0.39–0.89; p = 0.012). Low-dose naltrexone showed a hazard ratio of 5.04 for improvement versus physical therapy alone among 108 patients (p = 0.02), and 52–67% of patients in observational studies reported improvements. In a randomized study of 30 patients with PASC and lung fibrosis, nintedanib and pirfenidone improved pulmonary function, 6MWT distance, and oxygen saturation over 12 weeks; nintedanib was associated with diarrhea (80%) and nausea/vomiting (66.6%). The STOP-PASC trial of a 15-day NMV-r course failed to show significant benefit. Ivermectin had no effect on PASC incidence in COVID-OUT, and remdesivir randomized trials showed no clear long-term benefit. The authors state limitations include heterogeneity of PASC symptoms and limited robust evidence.

  18. Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
    Summary

    This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.

  19. A Perspective on the Role of Metformin in Treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID.2025 · review
    Summary

    This perspective review assessed metformin for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID (LC); the authors enrolled no patients and reported no primary study data. It discusses mechanisms and summarizes other studies. Bramante et al. was described as a multiarm, multiagent, parallel-grouped, phase three trial with an initial n of 6602; confirmed LC by day 300 was 8.3% of that initial n, and the metformin group showed a reduction of 41% when started within 3 days of COVID-19 symptom onset. Reis et al. reported a relative risk of 1.14 (0.73–1.81) for metformin worsening the primary outcome, with 21.9% of the Metformin group dropping out compared with 11.8% of the placebo group. Ventura-Lopez et al. reported reduced acute COVID-19 severity and viral load with 620 mg Metformin Glycinate twice daily. A Hubei retrospective cohort reported higher acidosis and lactic acidosis in the metformin group (2.95%, 1.77% vs 1.5%, 0.75%), lower heart failure (HR 0.61 p = 0.006) and ARDS (HR 0.66 p = 0.028), and no significant difference in mortality. Bullón treated six fibromyalgia patients with 200 mg/day of metformin, with reduced symptoms on the Fatigue Inventory Questionnaire and a significant decrease in fatigue. The review also lists dose-dependent side effects such as diarrhea, nausea and abdominal pain in 20% of cases. The authors state more research is needed to refine dosing and delivery methods.

  20. Pharmacological evaluation of vitamin D in COVID-19 and long COVID-19: recent studies confirm clinical validation and highlight metformin to improve VDR sensitivity and efficacy.2024 · review
    Summary

    This review examined published articles from January 2022 to August 2023 on vitamin D in COVID-19 and long COVID-19 and on metformin. It included 58 clinical studies and described observational studies, randomized controlled trials and meta-analyses; articles were collected from electronic databases. Vitamin D was given in varied doses and durations, including 4,000 IU daily for 30 days, 10,000 IU/day for 14 days, 50,000 IU weekly for 2–3 weeks, 140,000 IU, 200,000 IU, 400,000 IU, 500 000 IU, and calcifediol 450 mcg each on two consecutive days. Comparisons included placebo, no supplementation, low versus high dose, and standard-dose cholecalciferol. Outcomes included SARS-CoV-2 infection, severity, ICU admission, mechanical ventilation, mortality, hospital stay, oxygen need and inflammatory markers. Some studies reported lower infection, severity, ICU admission, ventilation or mortality; others reported no effect, including Mariani et al. (218 adults), Jolliffe et al. (3100 participants), Zhang et al. (3359 patients), Abroug et al. (117 patients), and Cannata-Andía et al. Villasis-Keever et al. reported no serious AEs; Sarhan et al. reported fewer adverse outcomes compared with low-dose vitamin D. Metformin was reported with about 41% reduction in long Covid versus placebo. Worsening and stopping counts were not reported.

  21. Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases2024 · review
    Summary

    This paper is an Opinion review, not a primary study; it reports no own participants, location, treatment duration, or primary outcome. It summarizes literature found in pubmed as of 09/25/2023: five prospective studies (plus 2 for Long COVID), 7 RCT (plus 2 for Long COVID) and 12 meta-analyses. The review discusses antidepressants for prevention of severe COVID-19 and Long COVID. In its Long COVID table, named entries include fluvoxamine (2 × 50 mg) for Bramante et al. 2022, marked 0; fluoxetine for Farahani et al. 2023, marked (+) Fluoxetine (Fatigue); vortioxetine for Di Nicola et al. 2023, marked +; tricyclic AD for La Sala et al. 2023, marked + Tricyclic AD (2 Cases); AD for Fontera et al. 2022, marked +; SSRI for Rus et al. 2023 (N = 95), marked +; and SSRI for Sidky et al. 2023 (N = 17,933; preprint), marked +. For harms, the review states tolerability of AD was reported to be generally well across prospective, randomized controlled studies and meta-analyses presented in the table. Siripongboonsitti et al. 2023 is noted with no deaths in both the fluvoxamine and control group. The authors describe Long COVID evidence as limited but with first preliminary promising results for AD. The paper itself does not compare arms; it tabulates named studies, including placebo-controlled randomized studies. The recorded data do not report people who worsened or stopped.

  22. Treatable traits for long COVID.2023 · review
    Summary

    This comprehensive review asked how a treatable traits approach could be applied to long COVID. It combined an umbrella review of 22 systematic reviews identifying long COVID symptoms and complications with a systematic review of 18 randomized controlled trials of prevention or management. The trials tested many interventions, including metformin for 14 days during acute COVID-19 versus placebo, hyperbaric oxygen therapy versus sham, exercise training or respiratory muscle training versus usual care or sham, HD-tDCS versus sham, L-arginine plus liposomal vitamin C versus placebo, aromatherapy versus inert oils, and platelet-rich plasma injections versus saline. Outcomes included long COVID incidence, cognition, olfaction, dyspnoea, fatigue, exercise capacity and health-related quality of life. In one prevention trial, metformin was associated with reduced long COVID incidence at 10 months (hazard ratio 0.58 [95% CI 0.38, 0.88]) among 564 metformin and 561 placebo participants; ivermectin and fluvoxamine showed no significant benefit. For management, hyperbaric oxygen improved cognition compared with sham (104.1 ± 7.2 versus 101.3 ± 8.9, p = 0.038), and exercise training improved exercise capacity compared with exercise advice (38.9 ± 10.8 versus 36.1 ± 9.5 mL/kg/min, p = 0.035). Some studies found no significant between-group differences, including a larger exercise trial. Adverse events included 13 during hyperbaric oxygen versus 14 during control; one aromatherapy participant withdrew on day 13 with headaches, and one sham IMT participant withdrew for symptom exacerbation. The authors state the review was limited by not conducting a meta-analysis and by heterogeneity of the included systematic reviews.

  23. Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein-Barr virus and the gut-brain axis.2023 · review
    Summary

    This review examined biological mechanisms of long COVID and treatment strategies based on the gut–brain axis; it had no primary cohort, so no number of patients enrolled or analysed is reported for the review itself. It discusses faecal microbiota transplantation (FMT), SSRIs and antidepressants, fluvoxamine, probiotics and fermented foods, and vagus nerve stimulation (VNS) in long COVID or COVID-19. A population-based retrospective study is reported to associate baseline SSRIs with sigma-1 receptor agonism with reduced risk of long COVID. A randomized placebo-controlled double-blind trial of fluvoxamine (n = 42, 100 mg daily for 10 days) during active COVID-19 significantly reduced fatigue incidence 12 weeks after primary COVID-19 compared with placebo (n = 43); other symptoms except poor concentration were less in the fluvoxamine group, but statistical analysis did not reach significant differences because of low dose (100 mg daily). Probiotic supplementation for 30 days reduced nasopharyngeal viral load, lung infiltrates, and duration of digestive and non-digestive symptoms in adult symptomatic outpatients with COVID-19. A longitudinal cohort of COVID-19 patients (n = 200) showed a negative correlation between regular yogurt containing probiotics and disease severity. A meta-analysis of nine studies reported a significant (51%) reduction in symptom severity with probiotics. Transcutaneous auricular VNS (90 min twice a day for consecutive 7 days) caused significant reduction of C-reactive protein, interleukin-6, and depression score in hospitalized patients with COVID-19. Case reports reported FMT improved GI symptoms, abnormal blood immunity markers, and dysbiosis and attenuated severe symptoms. The review notes risk of Clostridioides difficile infection with FMT.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime